Literature DB >> 31960140

Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients.

Cristin D W Kaspar1, Isidora Beach2, Jennifer Newlin3, India Sisler3, Daniel Feig4, Wally Smith5.   

Abstract

BACKGROUND: Sickle cell nephropathy (SCN) is a progressive disease that contributes significant morbidity and mortality in sickle cell disease (SCD), yet it remains poorly understood. Hyperuricemia negatively impacts renal function in the non-sickle cell population but is understudied in SCD.
METHODS: We performed a cross-sectional analysis of the first 78 pediatric SCD patients enrolled in a cohort study. The mechanism of development of hyperuricemia (defined, serum uric acid (UA) ≥ 5.5 mg/dL) was characterized as a result of either UA overproduction or inefficient renal excretion by the Simkin index and fractional clearance of urate (FCU) equations. Associations between hyperuricemia and albuminuria or estimated glomerular filtration rate (eGFR) were determined by linear regression.
RESULTS: The prevalence of hyperuricemia in this young population (mean age 11.6 ± 3.77 years) was 34.2%. Only 1 hyperuricemic participant overproduced UA by Simkin index, while 62.5% were inefficient renal excretors of UA (FCU < 4%). Hyperuricemia was associated with a significant decrease in average eGFR, -27 ml/min/1.73m2 below normouricemia (mean eGFR 151.6 ± 40.32), p = 0.0122. Notably, the previously accepted association between decline of eGFR with age is significantly modified by hyperuricemia stratification, where hyperuricemia explains 44% of the variance in eGFR by age (R2 = 0.44, p = 0.0004) and is nonsignificant in normouricemia (R2 = 0.07, p = 0.0775).
CONCLUSION: These findings indicate that hyperuricemia may be associated with early eGFR decline in SCN. This association must be further characterized in prospective cohort studies in SCN, and hyperuricemia must be investigated as a potential therapeutic target for SCN.

Entities:  

Keywords:  Pediatric; Sickle cell disease; Sickle cell nephropathy; Uric acid

Mesh:

Substances:

Year:  2020        PMID: 31960140     DOI: 10.1007/s00467-019-04432-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  34 in total

1.  New standards for uric acid excretion and evidence for an inducible transporter.

Authors:  Peter A Simkin
Journal:  Arthritis Rheum       Date:  2003-10-15

2.  Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).

Authors:  Akira Sezai; Masayoshi Soma; Kin-ichi Nakata; Shunji Osaka; Yusuke Ishii; Hiroko Yaoita; Hiroaki Hata; Motomi Shiono
Journal:  J Cardiol       Date:  2015-01-31       Impact factor: 3.159

3.  Elevated uric acid increases the risk for acute kidney injury.

Authors:  Vijay Lapsia; Richard J Johnson; Bhagwan Dass; Michiko Shimada; Ganesh Kambhampati; Noel I Ejaz; Amir A Arif; A Ahsan Ejaz
Journal:  Am J Med       Date:  2012-03       Impact factor: 4.965

Review 4.  The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait.

Authors:  Rakhi P Naik; Vimal K Derebail
Journal:  Expert Rev Hematol       Date:  2017-10-30       Impact factor: 2.929

5.  Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.

Authors:  Kenichi Tanaka; Masaaki Nakayama; Makoto Kanno; Hiroshi Kimura; Kimio Watanabe; Yoshihiro Tani; Yoshimitsu Hayashi; Koichi Asahi; Hiroyuki Terawaki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2015-02-13       Impact factor: 2.801

6.  Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients.

Authors:  Shih-Ping Hsu; Mei-Fen Pai; Yu-Sen Peng; Chin-Kang Chiang; Tai-I Ho; Kuan-Yu Hung
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

7.  Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality.

Authors:  D R Powars; D D Elliott-Mills; L Chan; J Niland; A L Hiti; L M Opas; C Johnson
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

8.  Uric acid: the oxidant-antioxidant paradox.

Authors:  Yuri Y Sautin; Richard J Johnson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-06       Impact factor: 1.381

9.  Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.

Authors:  Daniel I Feig; Beth Soletsky; Richard J Johnson
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

10.  Soluble Uric Acid Activates the NLRP3 Inflammasome.

Authors:  Tarcio Teodoro Braga; Maria Fernanda Forni; Matheus Correa-Costa; Rodrigo Nalio Ramos; Jose Alexandre Barbuto; Paola Branco; Angela Castoldi; Meire Ioshie Hiyane; Mariana Rodrigues Davanso; Eicke Latz; Bernardo S Franklin; Alicia J Kowaltowski; Niels Olsen Saraiva Camara
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

View more
  2 in total

1.  Renal Abnormalities among Sickle Cell Disease Patients in a Poor Management Setting: A Survey in the Democratic Republic of the Congo.

Authors:  Paul Kambale-Kombi; Roland Marini Djang'eing'a; Jean-Pierre Alworong'a Opara; Jean-Paulin Mbo Mukonkole; Vincent Bours; Serge Tonen-Wolyec; Dieu-Merci Mbumba Lupaka; Lucien Bolukaoto Bome; Charles Kayembe Tshilumba; Salomon Batina-Agasa
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-07-01       Impact factor: 3.122

2.  Hyperuricemia and Associated Factors in Children with Chronic Kidney Disease: A Cross-Sectional Study.

Authors:  Jie Xu; Lingxiao Tong; Jianhua Mao
Journal:  Children (Basel)       Date:  2021-12-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.